-
December 28, 2019Elpiscience Completes Series B Financing of USD $100 Million
December 28, 2019, Shanghai, China, Elpiscience Biopharma announces the completion of Series B financing of 100 million USD. The round was led by Hyfinity Investments, with participation from Tencent,...
-
September 19, 2019Elpiscience to Present ES002/ES004 Data at SITC 2019
Shanghai September 19th 2019, Elpiscience Biopharma, Ltd., a clinical stage immuno-oncology company, announced that it will present data of anti-CD39 and anti-SIRPα antibodies, ES002 a...
-
September 10, 2019Elpiscience Received Second Prize in Merck’s Advance Biotech Grant Program
Shanghai Sep 10th 2019, Elpiscience Biopharma, Ltd., announced that it received the Second Prize, which is valued at 1 million RMB, in the Advance Biotech Grant program sponsored by Merck. T...
-
August 27, 2019Elpiscience Announces Advancement of Two Discovery Molecules into CMC
Shanghai Aug 27th 2019, Elpiscience Biopharma, Ltd., a clinical stage immuno-oncology company, announces that two key molecules in innate immunity have entered into CMC development stage. ...
-
July 16, 2019Elpiscience: Official Opening of Shanghai R&D Center
On July 16th, 2019, Elpiscience Biopharmaceutical Ltd. (Elpiscience) announced the official opening of its Shanghai R&D Center. In less than two years since its inception, the company has establis...
-
June 28, 2019ES101: First Patient Dosing in Phase I Clinical Trials
On June 28, 2019, Elpiscience Biopharmaceutical Ltd. announced first-patient dosing of first-in-class bispecific antibody ES101, targeting both PD-L1 and 4-1BB, at Shanghai East Hospital. This is...